Publications
Manuel G. Afable II, Michael J. Clemente, Andres Jerez, Li Zhang, Holleh Husseinzadeh, Hanna Rajala, Satu Mustjoki, Hideki Makishima, Brittney E. Dienes, John Desamito, Alan Lichtin, Mikkael A. Sekeres, Brad Pohlman, Anjali Advani, Ramon V. Tiu, Jaroslaw P. Maciejewski.. Large Granular Lymphocytic: Common Therapies and their Outcomes Journal of Hematology and Transfusion. 2014. PMID:
Penny K. Sneed, Norbert Kased, James L. Rubenstein. 50 Brain Metastases and Neoplastic Meningitis. . 2014. PMID:
Tsai KK, Zarzoso I, Daud AI. PD-1 and PD-L1 antibodies for melanoma. Human vaccines & immunotherapeutics. 2014. PMID: 25625924
Beck JT, Hortobagyi GN, Campone M, Lebrun F, Deleu I, Rugo HS, Pistilli B, Masuda N, Hart L, Melichar B, Dakhil S, Geberth M, Nunzi M, Heng DY, Brechenmacher T, El-Hashimy M, Douma S, Ringeisen F, Piccart M. Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2. Breast cancer research and treatment. 2013. PMID: 24362951
Asmussen J, Lasater EA, Tajon C, Oses-Prieto J, Jun YW, Taylor BS, Burlingame A, Craik CS, Shah NP. MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction. Cancer discovery. 2013. PMID: 24362263
Dhruva A, Hecht FM, Miaskowski C, Kaptchuk TJ, Bodeker G, Abrams D, Lad V, Adler SR. Correlating traditional Ayurvedic and modern medical perspectives on cancer: results of a qualitative study. Journal of alternative and complementary medicine (New York, N.Y.). 2013. PMID: 24341342
Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P, Cortes J, Kantarjian H, Shah NP. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leukemia Research. 2013. PMID: 24374145
Verstovsek S, Tam CS, Wadleigh M, Sokol L, Smith CC, Bui LA, Song C, Clary DO, Olszynski P, Cortes J, Kantarjian H, Shah NP. Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leukemia Research. 2013. PMID: 24374145
Smith CC. Disease diversity and FLT3 mutations. Proceedings of the National Academy of Sciences of the United States of America. 2013. PMID: 24324154
Merriman JD, Aouizerat BE, Cataldo JK, Dunn L, Cooper BA, West C, Paul SM, Baggott CR, Dhruva A, Kober K, Langford DJ, Leutwyler H, Ritchie CS, Abrams G, Dodd M, Elboim C, Hamolsky D, Melisko M, Miaskowski C. Association between an interleukin 1 receptor, type I promoter polymorphism and self-reported attentional function in women with breast cancer. Cytokine. 2013. PMID: 24315345
Merriman JD, Aouizerat BE, Cataldo JK, Dunn L, Cooper BA, West C, Paul SM, Baggott CR, Dhruva A, Kober K, Langford DJ, Leutwyler H, Ritchie CS, Abrams G, Dodd M, Elboim C, Hamolsky D, Melisko M, Miaskowski C. Association between an interleukin 1 receptor, type I promoter polymorphism and self-reported attentional function in women with breast cancer. Cytokine. 2013. PMID: 24315345
Politi J, Shah NP. What does a deep molecular response signify? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013. PMID: 24297955
Newman RG, Ross DB, Barreras H, Herretes S, Podack ER, Komanduri KV, Perez VL, Levy RB. The allure and peril of hematopoietic stem cell transplantation: overcoming immune challenges to improve success. Immunologic research. 2013. PMID: 24272856
Komanduri KV, Wieder ED, Benjamin CL, Levy RB. The evolving art of hematopoietic stem cell transplantation: translational research in post-transplant immune reconstitution and immunosuppression. Immunologic research. 2013. PMID: 24242818
Díaz-Montero CM, Zidan AA, Pallin MF, Anagnostopoulos V, Salem ML, Wieder E, Komanduri K, Montero AJ, Lichtenheld MG. Understanding the biology of ex vivo-expanded CD8 T cells for adoptive cell therapy: role of CD62L. Immunologic research. 2013. PMID: 24218360
Martin TG. Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib. Oncology (Williston Park, N.Y.). 2013. PMID: 25184230
Pritchard KI, Burris HA, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, Campone M, Csöszi T, Baselga J, Puttawibul P, Piccart M, Heng D, Noguchi S, Srimuninnimit V, Bourgeois H, Gonzalez Martin A, Osborne K, Panneerselvam A, Taran T, Sahmoud T, Gnant M. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clinical breast cancer. 2013. PMID: 24267730
Subramaniam S, Kelley RK, Venook AP. A review of hepatocellular carcinoma (HCC) staging systems. Chinese clinical oncology. 2013. PMID: 25841912
Subramaniam S, Kelley RK, Venook AP. A review of hepatocellular carcinoma (HCC) staging systems. Chinese clinical oncology. 2013. PMID: 25841912
Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Richey S, Roach M, Rohren E, Rosenfeld S, Small EJ, Srinivas S, Stein C, Strope SA, Tward J, Walsh PC, Shead DA, Ho M, National comprehensive cancer network. Prostate cancer, version 1.2014. Journal of the National Comprehensive Cancer Network : JNCCN. 2013. PMID: 24335682